• Contact ArQule
  • About ArQule
  • Product R & D
    • Pipeline
    • C-Met/Tivantinib Program
    • ArQule Kinase Inhibitor Platform (AKIP)
  • Clinical Trials
  • Investors and Media
  • Careers
Home : Product R & D : Pipeline

Pipeline

Print Version
Product Program Partner Research Pre-Clinical Development Phase I Phase II Phase III
ONCOLOGY
Tivantinib (ARQ 197)6 C-Met Inhibitor Daiichi Sankyo4
Kyowa Hakko5





ARQ 621 Eg5 Inhibitor
ARQ 736 BRAF Inhibition
ARQ 087 FGFR Inhibition
ARQ 092 AKT Inhibitor

Portfolio Updated February 2012

1 Pre-GLP toxicology testing
2 Post-initiation of GLP toxicology testing
3 Designation follows initation of first patient enrollment and dosing in lead indication
4 U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries
5 Japan and select Asian countries
6 See corporate slide presentation here for the status of all ongoing trials with ARQ 197.

© ArQule, 2011 | Terms and Conditions: Purchasing | Terms of Use